Opposing Effects of Two Tissue Transglutaminase Protein Isoforms in Neuroblastoma Cell Differentiation

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2009 Dec 17

PMID 20007697

Citations 22

Authors

Andrew E L Tee

Glenn M Marshall

Pei Y Liu

Ning Xu

Michelle Haber

Murray D Norris

Siiri E Iismaa

Tao Liu

Affiliations

Soon will be listed here.

Abstract

We have demonstrated previously that the Myc oncoprotein blocks cancer cell differentiation by forming a novel transcriptional repressor complex with histone deacetylase and inhibiting gene transcription of tissue transglutaminase (TG2). Moreover, induction of TG2 gene transcription and transamidase activity is essential for the differentiating effects of retinoids in cancer cells. Here, we show that two structurally distinct TG2 protein isoforms, the full-length (TG2-L) and the short form (TG2-S), exert opposing effects on cell differentiation. Repression of TG2-L with small interfering RNA, which did not affect TG2-S expression, induced dramatic neuritic differentiation in neuroblastoma cells. In contrast, overexpression of TG2-S or a GTP-binding-deficient mutant of TG2-L (R580A), both of which lack the GTP-binding Arg-580 residue, induced neuroblastoma cell differentiation, which was blocked by an inhibitor of transamidase activity. Whereas N-Myc repressed and retinoid activated both TG2 isoforms, repression of TG2-L, but not simultaneous repression of TG2-L and TG2-S, enhanced neuroblastoma cell differentiation due to N-Myc small interfering RNA or retinoid. Moreover, suppression of vasoactive intestinal peptide (VIP) expression alone induced neuroblastoma cell differentiation, and VIP was up-regulated by TG2-L, but not TG2-S. Taken together, our data indicate that TG2-L and TG2-S exert opposite effects on cell differentiation due to differences in GTP binding and modulation of VIP gene transcription. Our findings highlight the potential importance of repressing the GTP binding activity of TG2-L or activating the transamidase activity of TG2-L or TG2-S for the treatment of neuroblastoma, and possibly also other Myc-induced malignancies, and for enhancing retinoid anticancer effects.

Citing Articles

Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death.

Aplin C, Zielinski K, Pabit S, Ogunribido D, Katt W, Pollack L Commun Biol. 2024; 7(1):982.

PMID: 39134806 PMC: 11319651. DOI: 10.1038/s42003-024-06672-x.

Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors.

Buccarelli M, Castellani G, Fiorentino V, Pizzimenti C, Beninati S, Ricci-Vitiani L Cells. 2024; 13(8.

PMID: 38667282 PMC: 11048792. DOI: 10.3390/cells13080667.

Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer.

Aguiari G, Crudele F, Taccioli C, Minotti L, Corra F, Keillor J Int J Biol Sci. 2022; 18(1):1-14.

PMID: 34975314 PMC: 8692156. DOI: 10.7150/ijbs.64167.

Structures of Human Transglutaminase 2: Finding Clues for Interference in Cross-linking Mediated Activity.

Kim G, Park H Int J Mol Sci. 2020; 21(6).

PMID: 32210142 PMC: 7139744. DOI: 10.3390/ijms21062225.

Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status.

Curro M, Ferlazzo N, Giunta M, Montalto A, Russo T, Arena S Int J Mol Sci. 2020; 21(4).

PMID: 32085516 PMC: 7072980. DOI: 10.3390/ijms21041364.

References

Pelengaris S, Khan M, Evan G . c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002; 2(10):764-76. DOI: 10.1038/nrc904. View

Iismaa S, Holman S, Wouters M, Lorand L, Graham R, Husain A . Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases. Proc Natl Acad Sci U S A. 2003; 100(22):12636-41. PMC: 240670. DOI: 10.1073/pnas.1635052100. View

Liu S, Cerione R, Clardy J . Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A. 2002; 99(5):2743-7. PMC: 122418. DOI: 10.1073/pnas.042454899. View

Balajthy Z, Csomos K, Vamosi G, Szanto A, Lanotte M, Fesus L . Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood. 2006; 108(6):2045-54. DOI: 10.1182/blood-2004-02-007948. View

Achyuthan K, Greenberg C . Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem. 1987; 262(4):1901-6. View

Singh U, Pan J, Kao Y, Joshi S, Young K, Baker K . Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem. 2002; 278(1):391-9. DOI: 10.1074/jbc.M206361200. View

Tatsukawa H, Fukaya Y, Frampton G, Martinez-Fuentes A, Suzuki K, Kuo T . Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology. 2009; 136(5):1783-95.e10. PMC: 4960455. DOI: 10.1053/j.gastro.2009.01.007. View

Liu T, Tee A, Porro A, Smith S, Dwarte T, Liu P . Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A. 2007; 104(47):18682-7. PMC: 2141837. DOI: 10.1073/pnas.0705524104. View

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

10.

Ruan Q, Tucholski J, Gundemir S, Johnson Voll G . The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase. Int J Clin Exp Med. 2008; 1(3):248-59. PMC: 2592594. View

11.

Lorand L, Graham R . Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003; 4(2):140-56. DOI: 10.1038/nrm1014. View

12.

Matthay K, Villablanca J, Seeger R, Stram D, Harris R, Ramsay N . Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341(16):1165-73. DOI: 10.1056/NEJM199910143411601. View

13.

Fraij B, Birckbichler P, Patterson Jr M, Lee K, Gonzales R . A retinoic acid-inducible mRNA from human erythroleukemia cells encodes a novel tissue transglutaminase homologue. J Biol Chem. 1992; 267(31):22616-23. View

14.

Lee J, Kim I, Kim S . Changes in gene expression with increased transglutaminase 2 in a SH-SY5Y cell line. Front Biosci. 2006; 11:2774-81. DOI: 10.2741/2007. View

15.

Matlin A, Clark F, Smith C . Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005; 6(5):386-98. DOI: 10.1038/nrm1645. View

16.

Begg G, Carrington L, Stokes P, Matthews J, Wouters M, Husain A . Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci U S A. 2006; 103(52):19683-8. PMC: 1750866. DOI: 10.1073/pnas.0609283103. View

17.

Iismaa S, Mearns B, Lorand L, Graham R . Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 2009; 89(3):991-1023. DOI: 10.1152/physrev.00044.2008. View

18.

Tucholski J, Lesort M, JOHNSON G . Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience. 2001; 102(2):481-91. DOI: 10.1016/s0306-4522(00)00482-6. View

19.

Antonyak M, Jansen J, Miller A, Ly T, Endo M, Cerione R . Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci U S A. 2006; 103(49):18609-14. PMC: 1654133. DOI: 10.1073/pnas.0604844103. View

20.

Citron B, Suo Z, SantaCruz K, Davies P, Qin F, Festoff B . Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int. 2001; 40(1):69-78. DOI: 10.1016/s0197-0186(01)00062-6. View